Limitations of pharmacogenomic predictor discovery in Phase II clinical trials
Pusztai L. Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pharmacogenomics 2007, 8: 1443-1448. PMID: 17979517, DOI: 10.2217/14622416.8.10.1443.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials, Phase II as TopicDrug TherapyGenetic MarkersHumansPharmacogeneticsReproducibility of Results